NCT03370627View on ClinicalTrials.gov

Effect of Anti-CD303 Antibodies in Autoimmune Diseases

NACompletedINTERVENTIONAL

Enrollment

138

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

May 25, 2019

Study Completion Date

May 25, 2019

Conditions

Immune Disease

Interventions

BIOLOGICAL

Monoclonal anti-cd303 antibody

Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.

Trial Locations (1)

Unknown

Hôpital Claude Huriez, CHU, Lille

All Listed Sponsors

collaborator

Laboratoire français de Fractionnement et de Biotechnologies

INDUSTRY

lead

University Hospital, Lille

OTHER

NCT03370627 - Effect of Anti-CD303 Antibodies in Autoimmune Diseases | Biotech Hunter | Biotech Hunter